Decision

Early access to medicines scheme (EAMS) scientific opinion: Nivolumab (for lung cancer)

This publication was withdrawn on

This scientific opinion has expired.

Information on the EAMS scientific opinion given to nivolumab for lung cancer, including the public assessment report.